Hepatic-arterial chemotherapy

Kemeny, Nancy E.; Fata, F. Ramón de

doi:10.1016/s1470-2045(00)00419-8

Cited by 63 publications

(30 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result might is not unexpected considering that trans-arterial treatment is generally accepted as a more effective approach than systemic treatments in liver tumors (24). In a biodistribution study employing intravenous administration of As 2 O 3 , the tissue concentration of monomethylarsinic acid, a major metabolite of As 2 O 3 , was highest in the lung and kidney, suggesting most of systemically administered As 2 O 3 is metabolized in organs other than the liver (25).…”

Section: Discussionmentioning

confidence: 80%

Effects of Arsenic Trioxide on Radiofrequency Ablation of VX2 Liver Tumor: Intraarterial versus Intravenous Administration

et al. 2012

View full text Add to dashboard Cite

Objective Arsenic trioxide (As 2 O 3 ) can be used as a possible pharmaceutical alternative that augments radiofrequency (RF) ablation by reducing tumor blood flow. The aim of this study was to assess the effect of intraarterial and intravenous administration of As 2 O 3 on RF-induced ablation in an experimentally induced liver tumor. Materials and Methods VX2 carcinoma was grown in the livers of 30 rabbits. As 2 O 3 (1 mg/kg) was administered through the hepatic artery (n = 10, group A) or ear vein (n = 10, group B), 30 minutes before RF ablation (125 mA ± 35; 90 ± 5℃). As a control group, 10 rabbits were treated with RF ablation alone (group C). RF was intentionally applied to the peripheral margin of the tumor so that ablation can cover the tumor and adjacent hepatic parenchyma. Ablation areas of the tumor and adjacent parenchymal changes among three groups were compared by the Kruskal-Wallis and Mann-Whitney U test. Results The overall ablation areas were 156 ± 28.9 mm 2 (group A), 119 ± 31.7 (group B), and 92 ± 17.4 (group C, p < 0.04). The ablation area of the tumor was significantly larger in group A (73 ± 19.7 mm 2 ) than both group B (50 ± 19.4, p = 0.02) and group C (28 ± 2.2, p < 0.01). The ratios of the tumoral ablation area to the overall ablation area were larger in group A (47 ± 10.5%) than that of the other groups (42 ± 7.3% in group B and 32 ± 5.6% in group C) ( p < 0.03). Conclusion Radiofrequency-induced ablation area can be increased with intraarterial or intravenous administration of As 2 O 3 . The intraarterial administration of As 2 O 3 seems to be helpful for the selective ablation of the tumor.

show abstract

Section: Discussionmentioning

confidence: 80%

Effects of Arsenic Trioxide on Radiofrequency Ablation of VX2 Liver Tumor: Intraarterial versus Intravenous Administration

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Increased response rates can be achieved by increasing the drug delivery to tumors [25]. Intraarterial chemotherapy is successfully used in cancer treatment [15,16] reaching a high first-pass extraction of the drug to the tumor. Therefore, intraarterial chemotherapy has a relative theoretical advantage over systemic chemotherapy, as high local drug concentrations with reduced toxicity can be achieved [26].…”

Section: Discussionmentioning

confidence: 99%

“…Intraarterial chemotherapy has been successfully used in cancer treatment [15,16] reaching a high first-pass extraction of the drug to the tumor. The method has been used in gastric cancer in a few trials [17,18] in an adjuvant setting to prevent the development of liver metastases [19] or in a neoadjuvant setting with encouraging results [20].…”

Section: Introductionmentioning

confidence: 99%

Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer

Tentes¹,

Markakidis²,

Karanikiotis³

et al. 2006

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“…1 Nicum et al, 2000). In particular, a derivative, 5-Fluoro-2 deoxyuridine (FUDR), is often continuously administered via a hepatic arterial pump or infusion (Kemeny et al, 1999;Kemeny and Fata, 2001;Tebbutt et al, 2002) and predominantly absorbed by the liver (Ensminger et al, 1978). The dose limiting toxicity for this intervention is hepatobiliary, with reports of inflammation surrounding the biliary tree together with fibrosis of the bile ducts and secondary chemical hepatitis (Cohen and Kemeny, 2003;Skitzki and Chang, 2002), indicating that the biliary duct epithelia are the most susceptible tissues.…”

Section: Introductionmentioning

confidence: 99%

The influence of toxicity constraints in models of chemotherapeutic protocol escalation

Boston

Gaffney

2011

Mathematical Medicine and Biology

View full text Add to dashboard Cite

The prospect of exploiting mathematical and computational models to gain insight into the influence of scheduling on cancer chemotherapeutic effectiveness is increasingly being considered. However, the question of whether such models are robust to the inclusion of additional tumour biology is relatively unexplored. In this paper, we consider a common strategy for improving protocol scheduling that has foundations in mathematical modelling, namely the concept of dose densification, whereby rest phases between drug administrations are reduced. To maintain a manageable scope in our studies, we focus on a single cell cycle phase-specific agent with uncomplicated pharmacokinetics, as motivated by 5-Fluorouracil-based adjuvant treatments of liver micrometastases. In particular, we explore predictions of the effectiveness of dose densification and other escalations of the protocol scheduling when the influence of toxicity constraints, cell cycle phase specificity and the evolution of drug resistance are all represented within the modelling. For our specific focus, we observe that the cell cycle and toxicity should not simply be neglected in modelling studies. Our explorations also reveal the prediction that dose densification is often, but not universally, effective. Furthermore, adjustments in the duration of drug administrations are predicted to be important, especially when dose densification in isolation does not yield improvements in protocol outcomes.

show abstract

Hepatic-arterial chemotherapy

Cited by 63 publications

References 67 publications

Effects of Arsenic Trioxide on Radiofrequency Ablation of VX2 Liver Tumor: Intraarterial versus Intravenous Administration

Effects of Arsenic Trioxide on Radiofrequency Ablation of VX2 Liver Tumor: Intraarterial versus Intravenous Administration

Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer

The influence of toxicity constraints in models of chemotherapeutic protocol escalation

Contact Info

Product

Resources

About